Abstract 337P
Background
The optimal dose and fractionation scheme for limited-stage small cell lung cancer remains controversial. Therefore, this study aimed to evaluate the safety and effectiveness of hyper-fractionated simultaneous Integrated Boost in Definitive Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Methods
The study cohort consisted of patients with pathologically diagnosed limited-stage small cell lung cancer (LS-SCLC) who received definitive chemoradiotherapy from January 2017 to December 2021. Eligible patients were administered twice-daily radiotherapy with simultaneous integrated boost IGRT (SIB-IGRT) of 54–60 Gy in 30 fractions to the gross tumor volume (GTV) and 45 Gy in 30 fractions to the planning target volume (PTV). The chemotherapy regimen was cisplatin/carboplatin in combination with etoposide. The primary endpoint was PFS and secondary endpoints included treatment-related adverse events (TRAEs) and OS.
Results
38 patients were finally enrolled, with a median age of 67.5. 86.8% of them were in the locally advanced stage. The median follow-up was 51.5 months. The 1-year, 2-year, and 5-year PFS were 70%, 55%, and 51% respectively, while the 1-year, 2-year, and 5-year OS were 89%, 76%, and 66%. Myelosuppression was the most common TRAEs. Grade 3–4 adverse events mainly consisted of neutropenia (47.4%), anemia (7.9%), thrombocytopenia (18.4%), esophagitis (13.1%), and pneumonia (2.6%).
Conclusions
This study demonstrates that high-dose hyper-fractionated SIB radiotherapy is effective and well-tolerated in patients with LS-SCLC, without prolonging treatment time, and may yield better survival outcomes.
Legal entity responsible for the study
Zigong Fourth People’s Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.